Skip to main content
ホーム / ニュース / Mubadala Invests in Global Biosimulation Leader Certara

Mubadala Invests in Global Biosimulation Leader Certara

ニュージャージー州プリンストン 2021 年 7 月 27 日: Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara.  The investment aligns with Mubadala’s strategy of enabling innovation to address unmet clinical needs and drive cost efficiencies.

Mubadala and certain existing institutional shareholders of Certara, including a shareholder affiliated with EQT, have entered into an agreement under which an affiliate of Mubadala will purchase an aggregate of 9,615,384 shares at $26 per share from the shareholders in a private transaction.  The transaction is scheduled to close on 2021 年 8 月 2 日.  EQT will remain a significant shareholder in the company after the transaction.

“We are pleased to welcome a significant new investment from Mubadala, a sovereign investor with deep expertise in life sciences that is focused on creating lasting value,” said William F. Feehery, Chief Executive Officer of Certara.  “As a newly listed public company, we are excited by Mubadala’s recognition of Certara’s performance and position as a global leader in biosimulation, especially as we execute on our next phase of growth.”

Camilla Languille, Head of Life Sciences at Mubadala, said, “Biosimulation is transforming traditional drug development via computational approaches that save time and cost throughout the entire biopharma R&D process. We are proud to have invested in Certara, whose industry-standard software is accelerating the development of new medicines that improve the lives of patients.”

Eric Liu, Co-Head of EQT’s Global Healthcare Sector Team, added, “We welcome Mubadala as a new shareholder of Certara. EQT remains a significant investor in Certara, and we look forward to continuing to support the management team in their efforts to accelerate medicines to patients through the use of biosimulation.”    

Certara(サターラ) について


About Mubadala Investment Company

Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi. 

Mubadala’s $243.4 billion (AED 894 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates.    

Headquartered in Abu Dhabi, Mubadala has offices in London, Rio de Janeiro, Moscow, New York, San Francisco and Beijing.

For more information about Mubadala Investment Company, please visit:

Forward-Looking Statements

当プレスリリースには将来に関する記述が含まれます。これらの記述は、米国の1995年私募証券訴訟改革法の「免責」事項に基づいて作成されました。サターラの信条や予想に関する記述を含め、歴史的事実ではない記述は将来に関する記述に該当します。将来に関する記述には、本質的にリスクや不確実性が含まれます。また様々な要因により、実際の結果が将来に関する記述に含まれるそれとは大きく異なるものになる可能性があります。These factors include, but are not limited to, (i) the failure of the transaction described above to close, or a delay in the anticipated closing date; (ii) any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; (iii) increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; (iv) our ability to compete within our market; (v) changes or delays in government regulation relating to the biopharmaceutical; and (vi) changes in EQT’s plans with respect to the Company. 将来に関する記述は、「だろう」「でしょう」「予定である」「予想される」「予測される」「目標とする」「目的とする」「推定される」「意図する」「計画する」「信じる」「可能性がある」「引き続き」「見込みである」やこれらに似た表現で特定できます。当プレスリリースで提供するあらゆる情報が当プレスリリースの日付時点のものであり、適用可能な法律の下で要求されない限り、サターラにはこうした情報を更新する義務はありません。

Investor Relations Contact:

David Deuchler
Gilmartin Group

Media Contacts:


赤津 笑美

Powered by GlobalLink OneLink Software